肾细胞癌 (RCC) 约占成人所有肾癌的 90-95%，其中透明细胞 RCC (ccRCC) 是最常见的亚型。 RCC 因其对免疫治疗的反应而闻名，这使其成为一个具有重要研究兴趣的领域。调节免疫监视的免疫检查点 (IC) 分子是 RCC 的既定治疗靶点。本研究的目的是分析十年观察期内 HVEM 和 CD160 基因多态性对 ccRCC 易感性和患者总生存期 (OS) 的影响。我们对 238 名 ccRCC 患者和 521 名对照者的三个 HVEM 单核苷酸多态性 (SNP) 进行了基因分型：rs1886730、rs2234167 和 rs8725，以及两个 CD160 SNP：rs744877 和 rs2231375。我们的研究结果表明，rs2231375 和/或 rs2234167 内的杂合性会增加 ccRCC 风险。此外，在女性中，HVEM SNP rs8725 和 rs1886730 内的杂合性也与 ccRCC 风险增加相关。 rs1886730、rs2234167、rs8725 和 rs2231375 的次要等位基因的存在也与 ccRCC 的某些临床特征相关。此外，rs1886730被发现与操作系统相关。总之，我们的研究强调了 HVEM 和 CD160 多态性与发生 ccRCC 和 OS 的风险之间的关联。

Renal cell carcinoma (RCC) accounts for approximately 90-95% of all kidney cancers in adults, with clear cell RCC (ccRCC) being the most frequently identified subtype. RCC is known for its responsiveness to immunotherapy, making it an area of significant research interest. Immune checkpoint (IC) molecules, which regulate immune surveillance, are established therapeutic targets in RCC. The aim of this study was to analyze the influence of HVEM and CD160 gene polymorphisms on ccRCC susceptibility and patient overall survival (OS) over a ten-year period of observation. We genotyped three HVEM single nucleotide polymorphisms (SNPs): rs1886730, rs2234167, and rs8725, as well as two CD160 SNPs: rs744877 and rs2231375, in 238 ccRCC patients and 521 controls. Our findings indicated that heterozygosity within rs2231375 and/or rs2234167 increases ccRCC risk. Furthermore, in women, heterozygosity within HVEM SNPs rs8725 and rs1886730 is also associated with an increased ccRCC risk. The presence of a minor allele for rs1886730, rs2234167, rs8725, and rs2231375 was also correlated with certain clinical features of ccRCC. Moreover, rs1886730 was found to be associated with OS. In conclusion, our study highlights an association between HVEM and CD160 polymorphisms and the risk of developing ccRCC as well as OS.